XBB.1.16‐RBD‐based trimeric protein vaccine can effectively inhibit XBB.1.16‐included XBB subvariant infection

Documenti analoghi

• Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1
  di: Lunzhi Yuan, et al.
  Pubblicazione: (2024)
• Combining Intramuscular and Intranasal Immunization With the MF59‐Adjuvanted Respiratory Syncytial Virus Pre‐Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice
  di: Jie Shi, et al.
  Pubblicazione: (2025)
• Intranasal Inoculation of Cationic Crosslinked Carbon Dots‐Adjuvanted Respiratory Syncytial Virus F Subunit Vaccine Elicits Mucosal and Systemic Humoral and Cellular Immunity
  di: Hong Lei, et al.
  Pubblicazione: (2025)
• Lessons from COVID‐19: Aspects of prevention, therapeutics, and diagnostics against SARS‐CoV‐2 with special focus on JN.1 and XBB sublineages
  di: Puja Jaishwal, et al.
  Pubblicazione: (2024)
• The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies
  di: Yishan Lu, et al.
  Pubblicazione: (2024)